Studies have shown the CD6-ALCAM pathway is overactive in the inflamed kidney and lungs of these patients. The potential of itolizumab to inhibit activation of multiple pro-inflammatory pathways ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback